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Objectives: The toll-like receptors (TLRs), including TLR4, have been shown to play a crucial role in
vascular inﬂammatory diseases, such as atherosclerosis and aneurysm. The main goal of this study was to
determine the potential of IAXO-102 (Innaxon, Tewkesbury), a novel small molecule TLR4 antagonist, to
modulate non-hematopoietic TLR4 proinﬂammatory signalling and inhibit experimental abdominal
aortic aneurysm (AAA) development.
Methods: Human umbilical vein endothelial cells (HUVEC) and Angiotensin II-induced experimental AAA
development were our in vitro and in vivo models respectively. Western blotting, antibody array and
ELISA approaches were used to explore the effect of IAXO-102 on TLR4 functional activity on two levels:
modulation of TLR4-induced mitogen activated protein kinases (MAPK) and p65 NF-kB phosphorylation
and expression of TLR4 dependent proinﬂammatory proteins.
Results: Following activation of TLR4, in vitro/in vivo data revealed that IAXO-102 inhibited MAPK and
p65 NF-kB phosphorylation associated with down regulation of the expression of TLR4 and TLR4
dependent proinﬂammatory proteins. Furthermore, IAXO-102 decreased Angiotensin II-induced aortic
expansion, rupture and incidence of AAA.
Conclusions: These results demonstrate the ability of IAXO-102 to negatively regulate TLR4 signalling and
to inhibit experimental AAA development, suggesting the potential therapeutic use of this TLR4 antag-
onist for pharmacological intervention of AAA.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The incidence of abdominal aortic aneurysm (AAA) is approxi-
mately 1e2% in men and 0.6e0.8% in women [1]. The natural his-
tory of most AAAs is to increase in size, increasing the risk of
rupture. Aneurysm rupture is the thirteenthmost common cause of
sudden death in men over 65 years [1] Surgical repair, using
endovascular stenting or open repair, both of which carry a sig-
niﬁcant risk of mortality, is the current treatment for this vascular
disease. Discovery of drugs for treatment and stabilisation of AAA isand Forensic Sciences, Anglia
.
irianov).
Ireland Ltd. This is an open accessa worthy challenge, with a signiﬁcant commercial impact to relieve
a signiﬁcant global ﬁnancial burden from the health services.
AAA is a complex vascular disease, involving the interaction of
several fundamental biological processes. The early events in
aneurysm formation, deﬁned largely from animal models, involve
inﬂammation as an initiating mechanism [2]. Toll-like receptors
(TLRs) serve as pattern recognition receptors, within the immune
system, and recognise exogenous ligands in response to inﬂam-
matory triggers. Among these receptors, TLR4 is known to be
activated by Gram-negative bacteria. However, TLR4 is also acti-
vated in response to other non-bacterial ligands (known as ligands
of sterile inﬂammation) such as heat shock proteins, ﬁbronectins,
small fragments of hyaluronan, and even saturated fatty acids and
extracellular matrix components in response to cellular damagearticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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such as the oxidised form of low density lipoprotein (LDL), have
also been shown to activate TLR4 [6]. TLR4 expression has been
described in the vascular system (endothelial cells and smooth
muscle cells) [7]. TLR4 has been reported to be implicated in in-
ﬂammatory related cardiovascular diseases. Importantly, recent
studies have demonstrated that deletion of the TLR4 gene protected
against experimental atherosclerosis and aneurysm development
or heart failure [8e10]. These ﬁndings strongly support the idea
that regulation of TLR4, and its endogenous ligands, appears as a
potential novel target for therapeutic control of aneurysms.
Manipulation of TLR4-mediated immune responses is a poten-
tial approach to treat a variety of inﬂammatory diseases. Over the
last years several TLR4 antagonists have been evaluated in pre-
clinical studies. However, only two drugs, E5564 (Eritoran, Eisai Inc)
and TAK-242 (Takeda Biological) progressed to clinical trials for
treatment of sepsis which have now been discontinued in different
phases [11,12].
Recently a panel of synthetic glycolipids, named IAXO com-
pounds, active as TLR4 antagonist [13] were developed by the
research group headed by Professor Peri at the University of Milano
Bicocca, Italy. Similarly to other cationic amphiphiles [14] IAXO
glycolipids are thought to modulate TLR4 activation and signalling
in vitro and in vivo by interfering selectively with the TLR4 co-
receptors CD14 and MD-2 [15e17].
The main aim of this study was to investigate the potential of
novel mimetic TLR4 antagonist, IAXO-102, for pharmacological
intervention in experimental AAA. Our results determined the
ability of IAXO-102 to negatively regulate a non-hematopoietic
TLR4 signalling and inhibit experimental AAA, suggesting the po-
tential therapeutic use of this TLR4 antagonist for treatment of
degenerative vascular diseases.
2. Materials and methods
2.1. Materials
TLR4 antagonists IAXO-102 and LPS (Salmonella minnesota (Re)
R595, TLRpure™) were kindly provided by Innaxon, Tewkesbury.
For in vitro experiments IAXO-102 (10 mM) was reconstituted in
ethanol. For in vivo experiments IAXO-102 was reconstituted in
Lipodisq™, a biodegradable liposomal nano-disc formulation
(Malvern Cosmeceutics, Malvern, UK) IAXO-102 in Lipodisq™ was
formulated and prepared by Innaxon, Tewkesbury. FITC conjugated
IAXO-102 was prepared by Professor Peri (University of Milan).
2.2. HUVEC
Human umbilical cord vein endothelial cells (HUVEC), pur-
chased from Promocell (Heidelberg, Germany), were treated in
accordance to the company's instructions. The cells were main-
tained at 37 C at 5% constant atmospheric condition of CO2 in
endothelial cell growth medium 2 (Promocell) in 25 cm2 ﬂasks pre-
coated with 1% attachment factor (Sigma UK). For all treatments,
HUVEC were used between passages 3 and 5. HUVEC were pre-
treated with IAXO-102 (0e10 mM) for 1 h, then exposed to LPS
(100 ng/ml) for 1 or 16 h.
2.3. Animal model
All animal experiments were approved by the local Animal
Research Work Ethical Review Board at St George's, University of
London. AAAswere induced in 6-month-old ApoE deﬁcient/C57Bl6,
as described previously [18]. Two in-vivo experiments were per-
formed; animals were sacriﬁced at 3 days (protein), and at 28 days(aortic diameter). Two groups (n ¼ 10) were infused with Angio-
tensin II (1 mg/min/kg), and the third (n ¼ 6) was infused with sa-
line. IAXO-102 was co-administered s.c. (3 mg/kg/day, 50 ml
Lipodisq™) and the remaining two groups were co-administered
s.c. with drug vehicle (50 ml Lipodisq™). At day 28, following
Angiotensin II infusion, computer-assisted micrometry measure-
ments deﬁned AAAs by reference to normal aortic measurements,
with an aneurysm being present when the maximum diameter of
the aorta exceeded 50% of the normal diameter; all measurements
were takenwhilst the aorta remained in-situ. In the sham-operated
group, the mean diameter of the suprarenal aorta was 0.86 mm,
and an aneurysmwas deemed to have formed when the maximum
diameter of the suprarenal aorta exceeded 1.29 mm.
2.4. Tissue collection and processing
Termination of the experiments was scheduled at 3 days after
insertion of the osmotic pumps. Animals were trans-cardially
perfused, at physiological pressures, with phosphate buffered sa-
line containing a cocktail of proteinase inhibitors (Sigma Aldrich,
UK) for 10 min at 4 C, after which the aortic tree was dissected at
4 C, removing the loose connective tissue around the exterior of
the artery. The thoracic, supra-renal and infra-renal aortic seg-
ments were harvested, frozen in liquid nitrogen, and stored
at 80 C until processed. Tissues were ground to a ﬁne powder
under liquid nitrogen and then lysed by sonication in a non-
denaturing phosphate lysis buffer (20 mM sodium phosphate,
137 mM NaCl, 25 mM sodium b-glycerophosphate, 2 mM sodium
pyrophosphate, 2 mM EDTA, 10% glycerol, 1% Triton X-100 and
protease inhibitor cocktail; SigmaeAldrich UK). Cell lysates were
incubated on ice for 20 min and centrifuged for 20 min at
13,000 rpm at 4 C. Supernatants were removed and the pellet of
insoluble material discarded. Protein concentration, of the cell su-
pernatant, was determined by the bicinchoninic acid method
(Pierce, Rockford, IL).
2.5. Western blot analysis of protein expression and
phosphorylation
Cell or tissue lysates (20 mg) were separated on a 10% SDS-PAGE
gel and transferred to polyvinyl diﬂuoride membranes (Bio-Rad,
UK) and blocked using 5% (wt/vol) skimmed milk in Tris-buffered
saline (TBS)/0.1% (vol/vol) Tween-20 for 1 h at room temperature.
Blots were incubated overnight at 4 C with primary antibodies:
phospho-JNK, phospho-p38, phospho-ERK, phospho-p65 NF-kB
and TLR4 from Cell Signalling Technology (NEB, Herts, UK)
(1:1000 dilution in TBS, 1% milk). After washing in TBS/0.1% (vol/
vol) Tween-20, blots were incubated with HRP-conjugated anti-
body at room temperature for 1 h in TBS/0.1% (vol/vol) Tween-20
and 5% milk. After the ﬁnal wash, immunoreactivity was visual-
ized using a chemiluminescent substrate ECL Plus (Healthcare,
Bucks, UK). Densitometric analysis was performed using GS-800
Calibrated Densitometer (Bio-Rad UK). The level of cellular actin
was used as a loading control.
2.6. Inﬂammation antibody array
Tissue protein lysates (20 mg) from supra-renal aortic segment
were semi-quantitatively analysed on Inﬂammation Antibody Arrays
(Ray-BioTech, containing 40 proinﬂammatory proteins) following
manufacturer's instructions. Brieﬂy, antibody array membranes
were incubated with protein lysates and then incubated with
antibody array biotinylated antibody. Finally the membranes were
incubated with streptavidin HRP-conjugated antibody. Immuno-
reactivity was visualized using a chemiluminescent substrate.
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Densitometer (Bio-Rad, UK).
2.7. ELISA
Human MCP-1 and IL-8 and mouse MIP-1g production were
measured in cell and tissue lysates (20 mg protein) using ELISA kits
(Ray-Bio Tech, USA) following the manufacturer's instructions. At
the ﬁnal stage absorbance was measured at 450 nm using a
microplatereader SpectraMax-340 (Molecular Devices, USA). Pro-
tein concentration was determined using SoftMax Pro5 software
package (Molecular Devices, USA).
2.8. Statistical analysis
Data are reported as mean ± SD and analysed with one-way
Anova followed by the Bonferroni post-hoc test for multiple com-
parisons using GraphPad Prism version 4.0. A value of P < 0.05 was
considered signiﬁcant.
3. Results
3.1. IAXO-102 negatively regulates TLR4 signalling in HUVEC
Changes in the functional activity of vascular endothelial cells
have been shown to play a critical role in vascular inﬂammatory
based diseases [19]. To test the ability of IAXO-102 to modulate
in vitro TLR4 signalling pathways we utilised HUVEC as an in vitro
model. To determine the effect of IAXO-102 on TLR4 signalling in
HUVEC we analysed two readouts: activation of MAPK/NF-kB as a
second messengers in TLR4 signalling and production of TLR4
dependent proinﬂammatory proteins.
Initially, we evaluated the effect of IAXO-102 on HUVEC viability.
HUVEC cells were exposed to different concentrations of IAXO-102
(0e20 mM) in the presence or absence of LPS (100 ng/ml) for up to
24 h. Results from MTT assay demonstrated that IAXO-102 did not
affect cell viability at concentrations up to 10 mM, however, IAXO-
102 at concentration of 20 mM reduced signiﬁcantly HUVEC
viability (Fig. 1 Supplement). Based on these data we have used
IAXO-102 up to 10 mM in the next series of experiments.
To investigate the effect IAXO-102 of MAPK/NF-kB activation in
TLR4 signalling, HUVEC were pre-treated with IAXO-102 (1e10 mM)
for 1 h and then exposed to LPS (100 ng/ml) for additional 1 h.
Western blot data revealed that JNK, p38, ERK and p65 NF-kB
phosphorylation was elevated in response to LPS in HUVEC (Fig. 1
and Fig. 2 Supplement). Pre-treatment of HUVEC with IAXO-102
clearly demonstrated the ability of this small molecule to signiﬁ-
cantly inhibit LPS-stimulated MAPK/p65nF-kB phosphorylation.
Importantly, the blocking effect of IAXO-102 was evident at con-
centrations of 10 mM, and to lesser extent at concentration of 1 mM
(Fig. 2 Supplement).
Having shown that IAXO-102 negatively regulated activation of
TLR4 second messengers MAPK/p65NF-kB in TLR4 signalling, we
next exploredwhether this small molecule could have an impact on
LPS-driven production of pro-inﬂammatory proteins in HUVEC.
Cells were pretreated with IAXO-102 (10 mM) for 1 h and then
exposed to LPS (100 ng/ml) for additional 16 h. Cell lysates were
analysed on human Inﬂammation Antibody Array (containing 40
proinﬂammatory proteins). The semi-quantitate analysis demon-
strated that LPS upregulated 20/40 proinﬂammatory proteins. In
contrast, IAXO-102 pretreatment inhibited, to different extent the
expression of 17/20 LPS driven proinﬂammatory proteins (Table 1
Supplement). MCP-1 and IL-8 are previously reported proin-
ﬂammatory proteins which are produced in vascular endothelial
cells in response to LPS and other inﬂammatory triggers [19]. Theyare both immune chemotactic factors and extravasation of immune
cells is an early event in the generation of lesions in this model.
Therefore, we validated the negative effect of IAXO-102 on MCP-1
and IL-8 expressions by ELISA. Again, IAXO signiﬁcantly blocked
LPS driven MCP-1 and IL-8 production in HUVEC (Fig. 2).
These data demonstrate that IAXO-102 is a negative regulator of
TLR4 signalling in HUVEC.
3.2. IAXO-102 downregulates TLR4 signalling in mouse aorta
Regression of experimental AAA by deletion of TLR4 was pre-
viously demonstrated, suggesting that TLR4 may represent a novel
therapeutic target to aneurysms treatment [8]. To test the potency
of IAXO-102 to modulate in vivo TLR4 signalling pathways we uti-
lised the Angiotensin II-driven experimental aneurysm develop-
ment as an in vivo model. Our previous studies demonstrated that
infusion of Angiotensin II in Apo E deﬁcient mice induced the in-
ﬂammatory process which was associated with an increase of TLR4
expression and production of proinﬂammatory proteins at 72 h in
mouse aorta [20].
Initially, we performed pharmacokinetic study to investigate the
distribution and clearance of IAXO-102-FITC (1 and 3 mg/kg)
following s.c. injection of IAXO-102-FITC in Apo-E deﬁcient C57BL/6
mice. Results demonstrated that IAXO-102-FITC was distributed in
different compartments of the animals and the signal was stable up
to 24 h of 1 mg/kg and up to 72 h of 3 mg/kg (data are not shown).
Analysis of target organs following 24 h injection showed that
IAXO-102-FITC was present in the bladder, small and large intes-
tine, to some extent, in kidney or liver (data are not shown). In
addition, FACS analysis of the blood taken from animals demon-
strated that IAXO-102-FITCwas boundmainly tomonocytes but not
to lymphocytes or granulocytes (Fig. 3 Supplement).
We monitored the effect of IAXO-102 in Lipodisq™ carrier on
TLR4 signalling in vivo on two levels: activation of MAPK/p65NF-kB
and production of proinﬂammatory proteins in three regions of the
mouse aorta at day 3 of Angiotensin II infusion. Our results
demonstrated that JNK, ERK and p65 NF-kB phosphorylation was
signiﬁcantly elevated in three regions (thoracic, supra-renal and
infra-renal) of mouse aortas following Angiotensin II infusion
(Fig. 3). In comparison with our previous published observations
[20.21] we found some differences in the JNK/ERK phosphorylation
proﬁle of different aortic segments that might be affected by the
nature of carrier and time of administration. Western blot analysis
clearly demonstrated the ability of IAXO-102 to signiﬁcantly inhibit
Angiotensin II-stimulated JNK/ERK/p65NF-kB phosphorylation
(Fig. 3). Furthermore, the blocking effect of IAXO-102was evident in
all three regions of mouse aortas.
We have previously reported that TLR4 receptor was dramati-
cally up-regulated in mouse aorta peaking 3 fold at 72 h following
Angiotensin II infusion [20]. Importantly, TLR4 up-regulation was
evident only in supra-renal but not in thoracic and infra-renal
aortic regions. Furthermore, immunoblotting data revealed that
TLR4 expression was signiﬁcantly down-regulated following co-
treatment with IAXO-102, suggesting that this site-speciﬁc effect
could be associated with modulation of experimental AAA forma-
tion (Fig. 4B).
We have previously documented that infusion of Angiotensin II-
induced production of a number of proinﬂammatory proteins in the
early stages of AAA development [20,21]. Having shown that IAXO-
102 could negatively regulate the second messengers’ activation in
TLR4 signalling and TLR4 expression, we next explored whether
this modulating effect could have an impact on Angiotensin II-
driven production of pro-inﬂammatory proteins in the initiation
stage of experimental aneurysm. Mouse tissue lysates were ana-
lysed on a human Inﬂammation Antibody Array (containing 40
Fig. 1. IAXO-102 inhibits LPS-induced MAPK/p65 NF-kB signalling in HUVEC. Cells were pre-incubated with IAXO-102 (I) (10 mM) for 1 h and then exposed to LPS (100 ng/ml) up to
60 min. Cell lysates were analysed for p38 (A), ERK (B), JNK (C) and p65 NF-kB (D) phosphorylation using immunoblotting analysis. Actin was used as a loading control. Data are
mean ± SD, n ¼ 4 at each data point. p*<0.05 and p**<0.01 [Anova].
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demonstrated that Angiotensin II infusion upregulated 22/40
proinﬂammatory proteins. In contrast, IAXO-102 pretreatment
inhibited, to varying extent, the expression of 14/22 Angiotensin II
driven proinﬂammatory proteins (Table 2 Supplement). Next, we
validated the blocking effect of IAXO-102 on MIP-1g expression by
ELISA. MIP-1g production was signiﬁcantly elevated in all three
regions of mouse aorta. Again, IAXO-102 treatment signiﬁcantly
inhibited production of MIP-1g in all three regions of the mouse
aorta (Fig. 4A).
These data demonstrate that IAXO-102 treatment is a negative
regulator of Angiotensin II driven inﬂammation and TLR4 signalling
is the target by which IAXO-102 exerts its effect.Fig. 2. IAXO-102 down regulates LPS driven MCP-1 and IL-8 production in HUVEC. Cells wer
ml) up to 24 h. Cell lysates were analysed for MCP-1and IL-8 expression using ELISA analy3.3. IAXO-102 inhibits the rupture, incidence and development of
experimental AAA
In our experimental model Angiotensin II infusion produced
mainly suprarenal AAA which was measured by computer-assisted
micrometry four weeks following Angiotensin II infusion. In addi-
tion, two mice from Angiotensin II only treated group developed a
thoracic aneurysm along with suprarenal AAA. Micrometry data
clearly demonstrated that co-treatment with IAXO-102 (3 mg/kg/
day) signiﬁcantly retarded Angiotensin II-induced increase in aortic
diameter (Fig. 5A). Aortic diameter in the IAXO-102 group was
signiﬁcantly smaller (1.055 ± 0.081 mm) than those in the positive
control group (1.865± 0.501) at four weeks following Angiotensin II
infusion. (Fig. 5 and Table 1). Furthermore, 30% of animals died of
aortic rupture and 86% of them developed AAA in the positivee pre-incubated with IAXO-102 (I) (1e10 mM) for 1 h and then exposed to LPS (100 ng/
sis. Data are mean ± SD, n ¼ 4 at each data point. p**<0.01 [Anova].
Fig. 3. IAXO-102 inhibits Angiotensin II-induced JNK, ERK and p65 NF-kB phosphorylation in the initiation stage of experimental AAA. Mice were divided into three groups: sham
control negative group, Angiotensin II group, Angiotensin II/IAXO-102 co-treated group. IAXO-102 (3 mg/kg/day in 50 ml Lipodisq™) was administered s.c. up to 72 h. Tissue samples
from thoracic aorta (TA); supra-renal aorta (SR) and infra-renal aorta (IR) were prepared at 72 h, and soluble proteins were analysed for JNK phosphorylation (A), ERK phos-
phorylation (B) and p-65 NF-kB phosphorylation (C) using immunoblotting analysis. Actin was used as a loading control. Data are mean ± SD, n ¼ 4 at each data point. p*<0.05
[Anova].
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completely abolished rupture, reduced aneurysm formation to
the level of 30% (Table 1) and increased mice survival (Fig. 5B). All
these data strongly support the clinical effect of IAXO-102 on
reducing aneurysm development and preventing aneurysm
rupture.4. Discussion
Although, primarily through cessation of smoking, the incidence
of AAAs are globally less, there remain a large number of AAAs
which will require eventually repairing by the costly, high risk,Fig. 4. IAXO-102 down regulates Angiotensin II-induced MIP-1g expression and TLR4 expre
sham control negative group (S), Angiotensin II group (A), Angiotensin II/IAXO-102 co-treate
72 h. Tissue samples from thoracic aorta (TA), supra-renal aorta (SR) and infra-renal aort
expression (TA, SR and IR) using ELISA (A) and TLR4 expression (SR) (B). Data are mean ±surgical process. Currently, management of modiﬁable risk factors
and surgical repair are the only redress for AAAs. The development
of a drug treatment for AAA remains a worthy goal with a great
commercial impact.
We show that a small molecule antagonist of TLR4 (IAXO-102)
has the potential to inhibit experimental AAAs, through a mecha-
nism associated with its ability to prevent vascular inﬂammation.
Inﬂammation has been documented as an early and critical
event in aneurysm formation. In this regard, a number of studies
have shown the essential role of TLR4 in several cardiovascular
pathologies, suggesting the beneﬁts of modulating TLR4 signalling
pathways [22]. Pharmacological intervention using TLR4ssion in the initiation stage of experimental AAA. Mice were divided into three groups:
d group (A/I). IAXO-102 (3 mg/kg/day in 50 ml Lipodisq™) was administered s.c. up to
a (IR) were prepared at 72 h, and soluble proteins were analysed for mouse MIP-1g
SD, n ¼ 4 at each data point. p*<0.05 [Anova].
Fig. 5. IAXO-102 inhibits Angiotensin II-induced development, incidence and rupture of experimental AAA and increases mice survival. Twenty six 6 month old male Apo-E
deﬁcient C57BL/6 mice were divided into three groups: sham control negative group, Angiotensin II group, Angiotensin II/IAXO-102 co-treated group. All animals had osmotic
pumps implanted at time 0. The sham group (n ¼ 6) had pumps delivering saline whereas the other two groups (n ¼ 10) had pumps delivering Ang II (1 mg/min/kg). The Angiotensin
II/IAXO-102 co-treated group received s.c. injections of IAXO-102 (3 mg/kg/day in 50 ml Lipodisq™) whereas the other two groups received daily s.c. injections of vehicle (Lip-
odisq™). Animals were euthanized at day 28 after pump implementation and the maximal aortic diameter was measured by computer micrometry. Data are mean ± SD, n ¼ as
indicated. p***<0.001 [Anova].
Table 1
IAXO-102 inhibits expansion, incidence and rupture of experimental AAA.
Groups Mice number Early rupture (%) AAA incidence (%) Aortic diameter (mm ± SD)
Sham 6 0 0 0.86 ± 0.08
Ang II 10 30 86 1.86 ± 0.56
Ang II/IAXO-102 10 0 30 1.05 ± 0.18
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cades, however they failed in different stages of clinical trials and
generation of new TLR4 modulators is of great interest [11,12].
We, and other groups, have found that early stages of experi-
mental AAA development are associated with production of
proinﬂammatory proteins in the experimental model of Angio-
tensin II infusion in hypercholesterolemic mouse [20,23]. TLR4
signalling plays an essential role in propagation of inﬂammation
and mediates production of large proportion of these proin-
ﬂammatory proteins. Recently, it was reported that TLR4 deﬁciency
attenuated AAA and atherosclerosis development, suggesting that
TLR4 signalling is fundamental in these vascular pathologies [8].
Intriguingly, TLR4 signalling exerted effects through non-
hematopoietic cell types, suggesting that vascular cells might use
TLR4 signalling network in response to inﬂammatory environment
[8].
We examined the potential of IAXO-102 to modulate in vivo
TLR4 signalling utilising a well-established model of Angiotensin II
driven AAA in hypercholesterolemic Apo E deﬁcient mouse. Using
nano-carriers, Lipodisq™ we were able to deliver the required
concentration of IAXO-102 which has poor solubility in organic
solvents. A similar nano-particle approaches to drug delivery has
been used for administration of anticancer compounds, such as
Doxorubicin for targeted delivery [24]. Pharmacokinetic studies
using IAXO-102-FITC demonstrated that the dose of 3 mg/kg was
sufﬁcient to produce stable signal and drug distribution among
several organs. In addition, blood sample analysis revealed that
IAXO-102 in predominantly bound to monocytes but not to lym-
phocytes or granulocytes. Data from the literature have shown a
differential TLR4 or CD14 expression among different types of im-
mune cells including lymphocytes and granulocytes [25]. In our
hands, we found that TLR4/CD14 are expressed in vascular cells
from human or mouse origin (data are not shown). Since IAXO-102
has been shown to interfere with TLR4/CD14 complex, it is possible
that IAXO-102 requires the presence of this complex for modula-
tion of TLR4 signalling in different types of immune and non-
immune cells [26].It has beenwell established that Angiotensin II infusion induced
a site speciﬁc AAA formation in suprarenal region of the mouse
aorta [27]. In this study, we examined not only the supra-renal
region of mouse aorta, but also the thoracic and infra-renal re-
gions. Comparative analysis of signal events in those three aortic
regions are a useful tool to identify site speciﬁc targets or signalling
events for IAXO-102 action.
Several evidences from the literature, including our data, high-
light the role of MAPK in AAA development [20,21,28]. All three
subclasses of MAPK have been shown to be activated in Angiotensin
II-induced AAA formation. JNK has been shown as important target
for AAA treatment demonstrating that JNK inhibitor markedly re-
duces aneurysmal size [29]. Previously, we have identiﬁed JNK as a
non-site speciﬁc target by which Rosiglitazone inhibited inﬂam-
matory responses and AAA development in this experimental
model [20]. Similarly, in this study IAXO-102 efﬁciently inhibited
JNK/ERK phosphorylation in all three origins of mouse aorta.
Notably, this small molecule was able to block a suprarenal site of
Angiotensin II-induced upregulation of TLR4. IAXO-102 was origi-
nally generated as a small molecule to block TLR4/CD14 in-
teractions [26]. It is possible therefore, by blocking formation of
TLR4/CD14 complex IAXO-102 to stimulate internalization and
degradation of TLR4 rather to have an impact on TLR4 gene
expression. Further studies are needed to clarify this issue.
Similarly to Rosiglitazone in this model, IAXO-102 negatively
regulated 50% ofmouse TLR4 dependent proinﬂammatory proteins.
Validation analysis demonstrated that IAXO-102 downregulated
MIP-1g in all three regions of mouse aorta, suggesting that this
effect is not site speciﬁc. Activation of NF-kB signalling plays a
critical role in production of TLR4 dependent proteins. In this study,
IAXO-102 administration inactivated NF-kB pathways supporting
its potential application for treatment of vascular inﬂammatory
based diseases.
These results clearly demonstrated the ability of IAXO-102 to
block the progression of inﬂammation by inhibiting the important
TLR4 dependent proinﬂammatory mediators in the mouse aorta.
Although the protein sequence of TLR4 is conserved across
C. Huggins et al. / Atherosclerosis 242 (2015) 563e570 569species, they differ considerably with regard to their function, for
example with regard to ligand discrimination or adaptor selec-
tion between human and mouse TLR4 [30]. Our data strongly
conﬁrm the ability of IAXO-102 to block both human and mouse
TLR4 signalling pathways. In contrast, TLR4 blocking antibodies
can inhibit TLR4 from speciﬁc species which make them un-
suitable to be used in both animal and human model systems. In
support, our screening analysis of several anti-human mono-
clonal TLR4 blocking antibodies demonstrated their ability to
affect human but not mouse TLR4 (data are not shown). The fact
that IAXO-102 was initially designed to block TLR4/CD14 in-
teractions may explain its broad biochemical properties [26].
Furthermore, this study also shows the potential of IAXO-102 to
modulate TLR4 signalling in response to distinct TLR4 ligands. In
our in vitro cell system (HUVEC) IAXO-102 blocked TLR4 in response
to well-known TLR4 speciﬁc agonist LPS. Data from the literature
indicates that the elevated level of cholesterol is a critical factor for
Angiotensin II induced experimental aneurysm, as wild type mice
do not develop aneurysms when infused with Angiotensin II
[31,32]. It has been demonstrated that artiﬁcial Angiotensin II
infusion triggers ‘sterile’ inﬂammation, the process that is nega-
tively regulated by TGF-b signalling which controls overproduction
of proinﬂammatory proteins, excessive macrophage activation, in-
hibition of matrix degradation and preservation of smooth muscle
cells survival in a wild type mice [33]. Furthermore, TGF-b signal-
ling has been reported to mediate the anti-inﬂammatory modula-
tion of TLRs including TLR4 [34].
Angiotensin II infusion triggers generation of reactive oxygen
species leading to formation of oxidised LDL in hyperlipidemic
mice [27]. In this relation we suggest that this small molecule
IAXO-102 inhibited Angiotensin II-induced TLR4 signalling acti-
vated by ligands of ‘sterile’ inﬂammation such as oxidised LDL or
small fragments of hyaluronan. In support to this notion, recent
data have demonstrated that oxidised LDL activated TLR4 sig-
nalling in vascular endothelial cells [35]. In addition, a small
fragments of hyaluronan have the potential to activate TLR4
pathways in vascular endothelium [36]. Furthermore, we found
that IAXO-102 partially downregulated TLR4 signalling in
response to minimally-oxidised LDL and small fragments of
hyaluronan in HUVEC [unpublished data]. This is an important
issue because different TLR4 ligands determine a speciﬁc signa-
ture in production of TLR4 dependent proteins with various
outcomes. On the other hand, it is believed that TLR4 activation
by ‘sterile’ ligands from non-bacterial origin are likely to
contribute to development of vascular diseases including aneu-
rysms [37].
Importantly, we have demonstrated that IAXO-102 exerted a
protective effect on aneurysm formation, incidence and rupture
suggesting the clinical relevance of using this compound for
treatment of AAAs. To date, Shang and colleagues have demon-
strated that Tanshinon IIA, a lipophilic component isolated from
Salvia multiorrhiza, inhibits elastase-induced AAA through TLR4/
MyD88 signalling, suggesting that TLR4 is an important pharma-
cological target for treatment of AAA [38].
In conclusion, the results from this study have demonstrated
for the ﬁrst time that a novel mimetic IAXO-102, the TLR4
antagonist, is effective in blocking vascular inﬂammation leading
to inhibition of experimental AAA development. While further
studies are required to investigate the modulating effect of IAXO-
102 on other processes (cell death, remodelling of extracellular
matrix or neoangiogenesis) associated with this complex vascular
disease the ﬁndings from this study suggest that IAXO-102 is a
potential new drug for pharmacological intervention of
aneurysms.Conﬂicts of interest
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